113 related articles for article (PubMed ID: 21975409)
1. In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer.
Alonso O; Gambini JP; Lago G; Gaudiano J; Quagliata A; Engler H
Clin Nucl Med; 2011 Nov; 36(11):1063-4. PubMed ID: 21975409
[No Abstract] [Full Text] [Related]
2. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
3. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
Sharma P; Mukherjee A; Bal C; Malhotra A; Kumar R
AJR Am J Roentgenol; 2013 Dec; 201(6):1340-7. PubMed ID: 24896203
[TBL] [Abstract][Full Text] [Related]
5. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.
Klingenstein A; Haug AR; Miller C; Hintschich C
Orbit; 2015 Feb; 34(1):16-22. PubMed ID: 25264824
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTANOC PET-CT demonstrating in vivo somatostatin receptor expression in idiopathic gynecomastia.
Dhull VS; Sharma P; Singla S; Singhal A; Bal C; Kumar R
Clin Nucl Med; 2013 Aug; 38(8):e324-5. PubMed ID: 23531768
[TBL] [Abstract][Full Text] [Related]
7. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma.
Sharma P; Dhull VS; Suman S; Bal C; Malhotra A; Kumar R
Clin Nucl Med; 2014 Apr; 39(4):374-5. PubMed ID: 23640227
[TBL] [Abstract][Full Text] [Related]
9. Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.
Kunikowska J; Królicki L; Pawlak D; Zerizer I; Mikołajczak R
Clin Nucl Med; 2012 Nov; 37(11):1052-7. PubMed ID: 22996234
[TBL] [Abstract][Full Text] [Related]
10. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangioendothelioma: Comparison With 18F-FDG.
Derlin T; Hueper K; Soudah B
Clin Nucl Med; 2017 Nov; 42(11):e478-e479. PubMed ID: 28872546
[TBL] [Abstract][Full Text] [Related]
13. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer relapse with PET/CT using a novel radiotracer.
Lilleby W; Willoch F; Stensvold A
Acta Oncol; 2012 Mar; 51(3):397-9. PubMed ID: 21936756
[No Abstract] [Full Text] [Related]
15. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.
Ambrosini V; Campana D; Allegri V; Opocher G; Fanti S
Clin Nucl Med; 2011 Jan; 36(1):64-5. PubMed ID: 21157217
[TBL] [Abstract][Full Text] [Related]
16. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
17. 'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs.
Basu S; Abhyankar A; Kand P; Kumar R; Asopa R; Rajan MG; Nayak U; Shimpi H; Das T; Venkatesh M; Chakrabarty S; Banerjee S
Nucl Med Commun; 2011 Jul; 32(7):654-8. PubMed ID: 21654355
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
[TBL] [Abstract][Full Text] [Related]
19. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
20. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
